JP2023540506A5 - - Google Patents
Info
- Publication number
- JP2023540506A5 JP2023540506A5 JP2023514771A JP2023514771A JP2023540506A5 JP 2023540506 A5 JP2023540506 A5 JP 2023540506A5 JP 2023514771 A JP2023514771 A JP 2023514771A JP 2023514771 A JP2023514771 A JP 2023514771A JP 2023540506 A5 JP2023540506 A5 JP 2023540506A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- lumateperone
- cocrystal
- diffraction pattern
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063075019P | 2020-09-04 | 2020-09-04 | |
| US63/075,019 | 2020-09-04 | ||
| PCT/US2021/071366 WO2022051770A2 (en) | 2020-09-04 | 2021-09-03 | Novel salts, crystals, and co-crystals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540506A JP2023540506A (ja) | 2023-09-25 |
| JP2023540506A5 true JP2023540506A5 (enExample) | 2024-09-11 |
Family
ID=80492079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023514771A Pending JP2023540506A (ja) | 2020-09-04 | 2021-09-03 | 新規の塩、結晶および共結晶 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230312573A1 (enExample) |
| EP (1) | EP4208434A4 (enExample) |
| JP (1) | JP2023540506A (enExample) |
| KR (1) | KR20230104121A (enExample) |
| CN (1) | CN116113622A (enExample) |
| AU (1) | AU2021338439A1 (enExample) |
| CA (1) | CA3186537A1 (enExample) |
| IL (1) | IL300886A (enExample) |
| MX (1) | MX2023002468A (enExample) |
| WO (1) | WO2022051770A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767410C2 (ru) | 2017-03-24 | 2022-03-17 | Интра-Селлулар Терапиз, Инк. | Новые композиции и способы |
| WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| US20250352469A1 (en) | 2024-05-16 | 2025-11-20 | Intra-Cellular Therapies, Inc. | Novel compositions, devices, and methods |
| CN118566395B (zh) * | 2024-08-02 | 2024-10-25 | 则正(济南)生物科技有限公司 | 测定甲苯磺酸卢美哌隆口崩片中杂质含量的方法、应用和系统 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3407889T3 (da) * | 2016-03-25 | 2021-08-09 | Intra Cellular Therapies Inc | Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet |
| US11014925B2 (en) * | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
| RU2767410C2 (ru) * | 2017-03-24 | 2022-03-17 | Интра-Селлулар Терапиз, Инк. | Новые композиции и способы |
| EP3609501A4 (en) * | 2017-04-10 | 2020-08-19 | Dr. Reddy's Laboratories Limited | AMORPHIC FORM AND SOLID DISPERSIONS OF LUMATEPERONE P-TOSYLATE |
| US11440911B2 (en) * | 2017-09-26 | 2022-09-13 | Intra-Cellular Therapies, Inc. | Salts and crystals |
| AU2019280850C1 (en) * | 2018-06-06 | 2025-02-13 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| CA3240552A1 (en) * | 2018-06-11 | 2019-12-19 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| US12144808B2 (en) * | 2018-08-29 | 2024-11-19 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| EP3887374A2 (en) * | 2018-11-27 | 2021-10-06 | Teva Pharmaceuticals International GmbH | Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof |
| WO2021007245A1 (en) * | 2019-07-07 | 2021-01-14 | Intra-Cellular Therapies, Inc. | Novel methods |
| US12478623B2 (en) * | 2019-09-25 | 2025-11-25 | Intra-Cellular Therapies, Inc. | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor |
-
2021
- 2021-09-03 IL IL300886A patent/IL300886A/en unknown
- 2021-09-03 CA CA3186537A patent/CA3186537A1/en active Pending
- 2021-09-03 EP EP21865304.6A patent/EP4208434A4/en active Pending
- 2021-09-03 WO PCT/US2021/071366 patent/WO2022051770A2/en not_active Ceased
- 2021-09-03 CN CN202180054461.5A patent/CN116113622A/zh active Pending
- 2021-09-03 MX MX2023002468A patent/MX2023002468A/es unknown
- 2021-09-03 US US18/043,959 patent/US20230312573A1/en active Pending
- 2021-09-03 KR KR1020237010822A patent/KR20230104121A/ko active Pending
- 2021-09-03 JP JP2023514771A patent/JP2023540506A/ja active Pending
- 2021-09-03 AU AU2021338439A patent/AU2021338439A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023540506A5 (enExample) | ||
| JP3621707B2 (ja) | ピリドン―縮合したアザ二環式―またはシチシン誘導体、その製法および嗜癖治療におけるその用途 | |
| JP2021527043A5 (enExample) | ||
| KR102345381B1 (ko) | 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 | |
| JP6592512B2 (ja) | 三環式アトロプ異性体の化合物 | |
| JP2009108082A (ja) | メタニコチン化合物のヒドロキシ安息香酸塩 | |
| JP2005509679A (ja) | ４−（１，３，４−チアジアゾール−２−イル）−１，４−ジアザビシクロ−［３．２．２］ノナン誘導体、それらの製造およびそれらの治療的使用 | |
| TW200529850A (en) | Methods of preparing aripiprazole crystalline forms | |
| JP2014074067A (ja) | メシル酸イマチニブのｆ、ｇ、ｈ、ｉおよびｋ結晶形 | |
| WO2013103724A1 (en) | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids | |
| HUE034460T2 (en) | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors | |
| TW201006813A (en) | Novel compounds | |
| HU197842B (en) | Process for producing pharmaceutical compositions comprising 2-alkoxy-n-(1-azabicyclo/2.2.2/oct-3-yl)-benzamide derivatives | |
| CN112638376B (zh) | 取代的四氢环戊二烯并[c]吡咯、取代的二氢吡咯嗪、其类似物和其使用方法 | |
| JP2005509681A (ja) | ４−（オキサゾロピリジン−２−イル）−１，４−ジアザビシクロ−［３．２．２］ノナン誘導体、それらの製造と治療的使用 | |
| JP2013544271A5 (enExample) | ||
| US20110306633A1 (en) | Selective m4 receptor antagonist and its medical use | |
| CN1452486A (zh) | 药物组合物和使用方法 | |
| KR100339115B1 (ko) | 결정성3-(4-헥실옥시-1,2,5-티아디아졸-3-일)-1,2,5,6-테트라하이드로-1-메틸피리딘(+)l-하이드로겐타르트레이트,이의제조방법및이를포함하는약제학적조성물 | |
| WO2009053742A2 (en) | Salts of nefopam and their use in therapy | |
| EA014738B1 (ru) | Гетероарилзамещенные диазатрициклоалканы, способы их получения и их применение | |
| JP2000516257A (ja) | タキキニンアンタゴニスト | |
| EP1809623A1 (en) | Process for the preparation of irbesartan hydrochloride | |
| JP2007269628A (ja) | 医薬化合物の結晶 | |
| US6683089B2 (en) | N-allyoxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-ols |